- March 15, 2019
Stetson University's Hatter Angel Network, a group of accredited investors composed of Stetson University alumni and faculty, has invested $135,000 in EVQLV, a leading biotechnology company that harnesses the power of artificial intelligence to accelerate drug discovery and development.
Stetson entrepreneurship students and several HAN members presented a ceremonial check to EVQLV at the Florida Venture Forum in Miami in early February 2023.
As with all HAN investments, the investment opportunity was first vetted by students as a class project and then pitched to the investors.
The investment is part of a larger funding round EVQLV has secured to develop its AI-driven platform, which streamlines the drug-discovery process by predicting and optimizing the properties of therapeutic antibodies.
With this investment, EVQLV plans to expand its team and bolster its infrastructure to continue delivering innovative solutions to the biotech industry.
"We are thrilled to support EVQLV's groundbreaking work in the field of biotechnology," said Dan Glunt, cofounder of the Hatter Angel Network and a Stetson University Entrepreneurship Advisory Board member and 1993 Stetson alumnus. "Their AI-powered platform has the potential to revolutionize drug development and ultimately improve patient outcomes. We are excited to see the impact this investment will have on EVQLV's growth trajectory."